title: Clinical experience and pharmacological effects of an oral contraceptive containing 20 micrograms oestrogen.
abstract: The performance of a new low-dose oral contraceptive (Mercilon) containing only 20 micrograms ethinyloestradiol combined with 150 micrograms desogestrel is reviewed. Eight multicentre clinical trials have been completed and provide information on 10,672 women studied over 73,477 cycles. The high efficacy of Mercilon was indicated by the finding that only 10 pregnancies were reported; nine of these occurred in women who omitted to take Mercilon on a number of days and only one in a woman who took all the tablets according to instructions. Cycle control was good; as with all oral contraceptives, the incidence of breakthrough bleeding and spotting was highest in the first treatment cycle and by the sixth treatment cycle the values were usually < 5% and < 7%. More than 80% of women had regular cycles. Side effects were few, the most common being headache, nausea and breast tenderness with incidences in the sixth treatment cycle of less than 2%, 6% and 6%, respectively. There were no significant changes in body weight or blood pressure. Pharmacodynamic investigations showed no adverse effects. Only 1 of 5 studies found an increased response to a glucose tolerance test compared to the pretreatment test. In 8 of 10 studies, serum HDL-C concentrations increased on treatment and this was associated with increases in apoproteins A1 and A2. Serum triglyceride levels also increased but no change occurred in serum cholesterol or LDL-C levels. Haematological factors were assessed in 8 studies and only minor changes were observed. Serum binding protein (SHBG, CBG, caeruloplasmin) concentrations increased and serum androgen levels decreased. Measurements of blood FSH, LH, oestradiol and progesterone indicated adequate inhibition of ovulation. Mercilon is the only oral contraceptive containing 20 micrograms ethinyloestradiol to have high efficacy, to have no adverse pharmacodynamic effects and, importantly, to produce an acceptable bleeding pattern not significantly different from that of oral contraceptives with a higher content of ethinyloestradiol.
authors.affiliation: Royal Postgraduate Medical School, London, UK.
authors.forename: K
authors.initials: K
authors.lastname: Fotherby
mesh_terms: D000328:Adult; D001798:Blood Proteins / Q000032:analysis; D050260:Carbohydrate Metabolism; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D050356:Lipid Metabolism; D010053:Ovary / Q000187:drug effects; D010197:Pancuronium / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology; D010902:Pituitary Gland / Q000187:drug effects
chemical_list: D001798:Blood Proteins; D010197:Pancuronium; C003549:dacuronium